Cencora, Inc. (NYSE:COR) Shares Bought by State Street Corp

State Street Corp boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 3.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,045,896 shares of the company's stock after buying an additional 291,867 shares during the quarter. State Street Corp owned approximately 4.08% of Cencora worth $1,810,970,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COR. New Millennium Group LLC purchased a new position in shares of Cencora during the 2nd quarter valued at approximately $26,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora in the second quarter valued at about $30,000. Concord Wealth Partners purchased a new stake in shares of Cencora during the third quarter worth about $30,000. SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $36,000. Finally, Ashton Thomas Securities LLC purchased a new position in Cencora in the 3rd quarter valued at about $41,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Trading Down 0.4 %

Shares of COR stock traded down $0.90 during trading on Friday, hitting $243.41. 1,199,812 shares of the stock traded hands, compared to its average volume of 1,126,541. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $253.27. The firm has a market capitalization of $47.05 billion, a P/E ratio of 32.41, a price-to-earnings-growth ratio of 1.65 and a beta of 0.45. The firm's fifty day moving average price is $237.12 and its 200-day moving average price is $233.46. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio is 29.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 93,018 shares of company stock worth $22,478,942. 15.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on COR. Bank of America reissued a "neutral" rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Leerink Partners decreased their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a report on Wednesday, August 21st. StockNews.com downgraded shares of Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Finally, UBS Group upped their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $276.80.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.